Companies in #Nephrology
Found 4 companies operating in this sector.
Akebia Therapeutics, Inc. is a fully integrated commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic solutions for patients with kidney disease. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia markets Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved by the U.S. FDA in March 2024 for the treatment of anemia due to chronic kidney disease in adult dialysis patients, and Auryxia® (ferric citrate) for hyperphosphatemia and iron deficiency anemia. In its Q3 2026 Form 10-Q filing on November 5, 2026, Akebia disclosed an implemented 7% workforce reduction (~14 roles out of 194 staff) to streamline operational expenses and align capital with core commercial priorities, recording $1.3 million in quarterly restructuring charges while holding $159.3 million in cash and cash equivalents.
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company developing targeted C3 therapies to inhibit the complement cascade in diseases of hematology, ophthalmology, and nephrology. The company has two FDA-approved C3 inhibitors: Empaveli (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH), and Syfovre for geographic atrophy (GA) secondary to age-related macular degeneration.
Kyowa Kirin Co., Ltd. is a Japanese specialty pharmaceutical and biotechnology company under the Kirin Holdings group, focused on developing innovative antibody-based drugs for cancer, kidney disease, immune system diseases, and rare diseases. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. Kyowa Kirin is the Japan-based parent of Kyowa Kirin, Inc. (the US subsidiary), and operates as a research-driven biopharma with multiple approved biologics including poteligeo (mogamulizumab, for cutaneous T-cell lymphoma) and Crysvita (burosumab, for X-linked hypophosphatemia). The company announced a $530M biologics manufacturing facility in Sanford, North Carolina in June 2024 — its first US manufacturing site — which was selected in June 2026 for the FDA PreCheck Pilot Program. Kyowa Kirin's US subsidiary (KKNA) operates the Sanford facility and supports the company's clinical and commercial biologics pipeline including rocatinlimab for atopic dermatitis.
Biopharmaceutical company focused on identifying, developing and commercializing therapies for rare diseases, with an emphasis on rare kidney and metabolic conditions; markets FILSPARI (sparsentan) for IgA nephropathy.